logo
Share SHARE
FONT-SIZE Plus   Neg

Genmab Announces First Phase III Trial Of Daratumumab - Quick Facts

Denmark-based biotechnology company Genmab A/S (GNMSF.PK) said its partner, Janssen Biotech, Inc. would begin a Phase III study of daratumumab in relapsed or refractory multiple myeloma. The trial would compare daratumumab in combination with lenalidomide and dexamethasone to lenalidomide and dexamethasone alone.

Genmab's Chief Executive stated: "The daratumumab development program is progressing very well. We are extremely pleased to be able to announce that this study evaluating daratumumab in combination with a core multiple myeloma treatment regime will initiate patient recruitment in the coming months."

The Phase III trial would comprise nearly 500 patients with relapsed or refractory multiple myeloma. Patients would be randomized to receive either daratumumab combined with lenalidomide and dexamethasone, or lenalidomide and dexamethasone alone. The company said the study's primary endpoint is progression free survival.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Uber has been reportedly tracking user's phones, even after deleting the app. However, the company now assured that it would not continue with such tracking anymore. Qatar Airways will launch long-haul flights to twelve new destinations in 2018, including direct flights to Wales in the UK and San Francisco in the U.S. Qatar Airways plans to start direct flights to San Francisco in early 2018 as part of its growth strategy. The move comes even as the carrier's Dubai-based rival Emirates Airlines said last week that it will cut flights to five cities in the U.S. Ahead of the April 28 launch of Mario Kart 8 for the Nintendo Switch game console, Target Corp. is transforming 650 plus stores across the country into Mario Kart courses. The transformation will begin at the front of the stores itself, with a checkered starting line at the entrance of the stores.
comments powered by Disqus
Follow RTT